Terme Magali, Colussi Orianne, Marcheteau Elie, Tanchot Corinne, Tartour Eric, Taieb Julien
INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, 56 rue Leblanc, 75015 Paris, France.
Clin Dev Immunol. 2012;2012:492920. doi: 10.1155/2012/492920. Epub 2012 Dec 24.
In the last decades a new class of therapeutic drugs have been developed that block tumor angiogenesis. These antiangiogenic molecules, which target VEGF or VEGFR, PDGFR, and c-kit, can act not only on endothelial cells but also on immune cells. Some antiangiogenic molecules inhibit the development of immunosuppressive mechanisms developed by the tumors to escape the immune system (such as regulatory T cells, myeloid-derived suppressor cells, and immunosuppressive cytokines). These immunomodulatory effects must be characterized in detail to enable a better prescription of these treatments. In this paper we will focus on the impact of anti-angiogenic drugs on immunosuppression and their potential combination with immunotherapeutic strategies. Interestingly, immune parameters or their modulation during treatment could serve as potential biomarkers of response or resistance to anti-angiogenic therapies.
在过去几十年中，已开发出一类新的治疗药物，可阻断肿瘤血管生成。这些抗血管生成分子靶向血管内皮生长因子（VEGF）或血管内皮生长因子受体（VEGFR）、血小板衍生生长因子受体（PDGFR）和原癌基因c-kit，不仅可作用于内皮细胞，还可作用于免疫细胞。一些抗血管生成分子可抑制肿瘤为逃避免疫系统而形成的免疫抑制机制（如调节性T细胞、髓源性抑制细胞和免疫抑制细胞因子）。必须详细表征这些免疫调节作用，以便更好地开具这些治疗药物的处方。在本文中，我们将重点关注抗血管生成药物对免疫抑制的影响及其与免疫治疗策略的潜在联合应用。有趣的是，治疗期间的免疫参数或其调节可作为抗血管生成治疗反应或耐药性的潜在生物标志物。
